Triple Receptor Mechanism Retatrutide is the first molecule to simultaneously engage all three receptors implicated in energy balance and body weight regulation: GLP-1 receptor: Reduces appetite, slows gastric emptying, improves glycemic control the same pathway as semaglutide (Ozempic/Wegovy) GIP receptor: Enhances insulin secretion and may contribute to fat mobilization the same dual pathway as tirzepatide (Mounjaro/Zepbound) Glucagon receptor: Increases energy expenditure, promotes hepatic fat oxidation, and drives thermogenesis a pathway unique to retatrutide among obesity therapeutics Clinical Significance In the Phase 2 trial published in the New England Journal of Medicine (2023), participants receiving the highest dose of retatrutide achieved a mean body weight reduction of 24.2% at 48 weeks with some participants losing over 30% of their body weight
Follow recommended dosage instructions carefully
Lindeman, Low blood glutathione levels in healthy aging adults , Journal of Laboratory and Clinical Medicine, 120 (5), 1992, s
10.1053/gast.1996.v110.pm8566578 64
Obesity and diabetes in the developing worlda growing challenge
It is prescription-only and used under a doctors supervision
